No licensed hantavirus vaccine is expected by the end of 2026 because all candidates remain in early preclinical or Phase 1 stages, with no Phase 3 efficacy trials completed or regulatory filings underway. Promising mRNA work by Moderna and Korea University, plus DNA candidates against Andes virus, has shown immunogenicity and protection in animal models and limited human safety data, yet these require years of additional testing, manufacturing scale-up, and large-scale efficacy studies hindered by the virus’s rarity and strain diversity. Recent outbreaks, such as the resolved MV Hondius cluster, have raised visibility but not accelerated timelines enough for approval before year-end. Only an unforeseen emergency-use pathway triggered by a major surge could alter this near-certain trader consensus.